# To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers

> **NCT02093819** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Placebo to BI 416970
- **DRUG:** BI 416970

## Key facts

- **NCT ID:** NCT02093819
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02093819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02093819, "To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02093819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*